Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone

Almeida, António; Pierdomenico, Francesca

doi:10.1016/j.leukres.2012.04.029

Cited by 12 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Keating et al reported a severe phototoxic reaction due to subcutaneous 5-azacitidine [6]. A case series of azacitidine-associated generalized urticarial skin rash has been reported in the literature, which resolved effectively after the use of concomitant low-dose oral steroids [7]. Lunge et al also described a biopsyproven case of leucocytoclastic vasculitis due to azacitidine, which resolved after discontinuation of the drug [8].…”

Section: Discussionmentioning

confidence: 99%

Reticular Skin Rash as an Adverse Effect of 5-Azacitidine

Verma¹,

Chandra²,

Shukla³

et al. 2022

Cureus

View full text Add to dashboard Cite

Azacitidine is a hypomethylating agent used for the treatment of patients with myelodysplastic syndrome (MDS). It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of MDS and is also indicated for the treatment of acute myeloid leukemia (AML). Injection site erythema, ecchymosis, and petechiae are some of the common cutaneous adverse reactions associated with azacitidine. This article describes a rare adverse cutaneous drug reaction with azacitidine in the form of a reticular generalized skin rash in a 28-year-old female with AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Reticular Skin Rash as an Adverse Effect of 5-Azacitidine

Verma¹,

Chandra²,

Shukla³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Additional treatment cycles beyond the sixth cycle can improve response rates in nearly half of patients. 5 There have been efforts to minimize the skin reactions due to 5-azacitidine. Some authors proposed topical administration of evening primrose oil immediately after 5-azacitidine injections in patients who had skin reactions with azacitidine in the past.…”

Section: Discussionmentioning

confidence: 99%

Severe phototoxic reaction secondary to subcutaneous 5-azacitidine

Keating

Dasanu

2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

Phototoxicity occurs when the effects of sunlight and certain drugs converge at the skin level. Various pharmacologic agents have been linked to photosensitivity, including agents used in hematology and oncology. We describe herein a severe phototoxic response to subcutaneous 5-azacitidine. There are no previous reports of phototoxicity reactions to this agent in the published literature. As 5-azacitidine is frequently used to treat patients with myelodysplastic syndromes and acute myeloblastic leukemia, familiarity with this side effect is important for the medical and scientific community at large.

show abstract

“…Ten cases manifested AE at multiple body sites including injection sites and were mostly accompanied by other symptoms represented by fever. Systemic cutaneous AE were clinicopathologically subcategorized as Sweet syndrome, neutrophilic panniculitis, urticarial rash, maculopapular erythematous eruption and erythema annulare centrifugum . In the remaining 11 cases, cutaneous AE were localized to the injection sites.…”

Section: Case Reportsmentioning

confidence: 99%

Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review

Shimoda‐Komatsu

Mizukawa

Takayama

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Subcutaneous injection of azacitidine (AZA) is an important treatment option for myelodysplastic syndrome (MDS), which improves overall survival. In hematology, the incidence of AZA‐induced cutaneous adverse events (AE) has been known to be relatively high, which has not been well recognized by dermatologists. Discontinuation of AZA can result in the deterioration of MDS disease activity. Therefore, on dermatological consultation, precise evaluation of AE severity and careful consideration is required for post‐AE medication management. To enhance our understanding of AZA‐induced cutaneous AE, we report four cases with two representative cutaneous AE subtypes and summarize the clinicopathological phenotypes and courses of the cases in the published work. Case 1, a 71‐year‐old man, developed neutrophilic dermatosis involving the dermis and subcutaneous tissue. The other three cases, a 75‐year‐old man, a 78‐year‐old woman and a 68‐year‐old man, presented injection‐site erythema associated with flare‐up reaction. Discontinuation of AZA was necessary for case 1 alone. The published work review delineated three major subtypes of AZA‐induced cutaneous AE: systemic cutaneous reaction, neutrophilic dermatosis type and erythematous type injection‐site reaction. Histologically, the first two subtypes are mostly characterized by neutrophil infiltration, while the third subtype presents lymphocytic cell infiltration. Neither AZA discontinuation nor intensive interventions were required for the erythematous type injection‐site reaction, while AZA termination or systemic treatments, represented by corticosteroid administration, were preferentially conducted for the systemic cutaneous reaction or the neutrophilic dermatosis type injection‐site reaction subgroup. These observations support the necessity of subtype‐dependent treatment strategies for the management of AZA‐induced cutaneous AE.

show abstract

Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone

Cited by 12 publications

References 5 publications

Reticular Skin Rash as an Adverse Effect of 5-Azacitidine

Reticular Skin Rash as an Adverse Effect of 5-Azacitidine

Severe phototoxic reaction secondary to subcutaneous 5-azacitidine

Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review

Contact Info

Product

Resources

About